Shares of CryoPort Inc (NASDAQ:CYRX) have been assigned an average recommendation of “Buy” from the six brokerages that are presently covering the firm, Marketbeat reports. Four analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $19.75.
A number of research firms have recently weighed in on CYRX. BidaskClub downgraded CryoPort from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 27th. ValuEngine upgraded CryoPort from a “buy” rating to a “strong-buy” rating in a report on Thursday, January 31st.
CYRX stock opened at $17.07 on Thursday. The firm has a market cap of $535.30 million, a PE ratio of -55.06 and a beta of 1.10. CryoPort has a twelve month low of $8.28 and a twelve month high of $18.11. The company has a quick ratio of 11.52, a current ratio of 11.57 and a debt-to-equity ratio of 0.42.
CryoPort (NASDAQ:CYRX) last released its earnings results on Thursday, May 2nd. The consumer goods maker reported ($0.08) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.08). The company had revenue of $6.65 million during the quarter, compared to the consensus estimate of $6.56 million. CryoPort had a negative return on equity of 28.30% and a negative net margin of 41.61%. The firm’s quarterly revenue was up 65.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.10) earnings per share. On average, equities research analysts predict that CryoPort will post -0.3 earnings per share for the current fiscal year.
In other CryoPort news, Director Richard J. Berman sold 30,000 shares of the stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $11.84, for a total value of $355,200.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 11.00% of the stock is owned by corporate insiders.
Several institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. boosted its position in shares of CryoPort by 35.9% during the third quarter. JPMorgan Chase & Co. now owns 216,523 shares of the consumer goods maker’s stock worth $2,774,000 after buying an additional 57,154 shares during the period. MetLife Investment Advisors LLC boosted its position in shares of CryoPort by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 18,910 shares of the consumer goods maker’s stock worth $242,000 after buying an additional 6,722 shares during the period. Teachers Advisors LLC boosted its position in shares of CryoPort by 10.4% during the third quarter. Teachers Advisors LLC now owns 53,085 shares of the consumer goods maker’s stock worth $680,000 after buying an additional 5,002 shares during the period. Rhumbline Advisers boosted its position in shares of CryoPort by 50.1% during the fourth quarter. Rhumbline Advisers now owns 33,919 shares of the consumer goods maker’s stock worth $374,000 after buying an additional 11,321 shares during the period. Finally, Creative Planning boosted its position in shares of CryoPort by 3.9% during the fourth quarter. Creative Planning now owns 610,019 shares of the consumer goods maker’s stock worth $6,729,000 after buying an additional 22,679 shares during the period. Institutional investors own 52.87% of the company’s stock.
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Featured Story: Total Return
Receive News & Ratings for CryoPort Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoPort and related companies with MarketBeat.com's FREE daily email newsletter.